Abstract | OBJECTIVES:
Proton pump inhibitors reduce ulcer recurrence in non-steroidal anti-inflammatory drug ( NSAID) users, but their impact in at-risk ulcer-free patients using the current spectrum of prescribed agents has not been clearly defined. We assessed esomeprazole for ulcer prevention in at-risk patients (> or = 60 yr and/or ulcer history) taking NSAIDs, including COX-2 inhibitors. Such studies are particularly relevant, given that concerns regarding adverse cardiovascular outcomes among COX-2 inhibitor users may prompt re-evaluation of their use. METHODS: We conducted two similar double-blind, placebo-controlled, randomized, multicenter studies; VENUS (United States) and PLUTO (multinational). A total of 844 and 585 patients requiring daily NSAIDs, including COX-2 inhibitors were randomized to receive esomeprazole (20 or 40 mg) or placebo, daily for 6 months. RESULTS: In the VENUS study, the life table estimated proportion of patients who developed ulcers over 6 months (primary variable, intent-to-treat population) was 20.4% on placebo, 5.3% on esomeprazole 20 mg (p < 0.001), and 4.7% on esomeprazole 40 mg (p < 0.0001). In the PLUTO study, the values were 12.3% on placebo, 5.2% with esomeprazole 20 mg (p = 0.018), and 4.4% with esomeprazole 40 mg (p = 0.007). Significant reductions were observed for users of both non-selective NSAIDs and COX-2 inhibitors. Pooled ulcer rates for patients using COX-2 inhibitors (n = 400) were 16.5% on placebo, 0.9% on esomeprazole 20 mg (p < 0.001) and 4.1% on esomeprazole 40 mg (p= 0.002). Esomeprazole was well tolerated and associated with better symptom control than placebo. CONCLUSIONS:
|
Authors | James M Scheiman, Neville D Yeomans, Nicholas J Talley, Nimish Vakil, Francis K L Chan, Zsolt Tulassay, Jorge L Rainoldi, Leszek Szczepanski, Kjell-Arne Ung, Dariusz Kleczkowski, Henrik Ahlbom, Jørgen Naesdal, Christopher Hawkey |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 101
Issue 4
Pg. 701-10
(Apr 2006)
ISSN: 0002-9270 [Print] United States |
PMID | 16494585
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Ulcer Agents
- Cyclooxygenase 2 Inhibitors
- Proton Pump Inhibitors
- Esomeprazole
|
Topics |
- Aged
- Anti-Inflammatory Agents, Non-Steroidal
(adverse effects, therapeutic use)
- Anti-Ulcer Agents
(therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Cyclooxygenase 2 Inhibitors
(adverse effects, therapeutic use)
- Double-Blind Method
- Duodenal Ulcer
(chemically induced, prevention & control)
- Esomeprazole
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Osteoarthritis
(drug therapy)
- Proton Pump Inhibitors
- Risk Factors
- Stomach Ulcer
(chemically induced, prevention & control)
|